Health Catalyst Announces ~$5 Million Stock Repurchase
Health Catalyst (HCAT) has announced a stock repurchase of approximately $5 million, executed between March 3-10, 2025. The company retired approximately 1.1 million shares of common stock as part of its existing share repurchase program, which was authorized in August 2022 with a total capacity of $40 million.
CEO Dan Burton stated that the repurchase reflects the company's confidence in its future, citing that current market prices don't reflect their long-term value. The company anticipates continued achievement of operating leverage and revenue growth reacceleration, emphasizing their commitment to creating sustainable value for shareholders, clients, and team members.
Health Catalyst (HCAT) ha annunciato un riacquisto di azioni per un valore di circa 5 milioni di dollari, effettuato tra il 3 e il 10 marzo 2025. L'azienda ha ritirato circa 1,1 milioni di azioni ordinarie come parte del suo programma di riacquisto di azioni esistente, autorizzato nell'agosto 2022 con una capacità totale di 40 milioni di dollari.
Il CEO Dan Burton ha dichiarato che il riacquisto riflette la fiducia dell'azienda nel suo futuro, sottolineando che i prezzi di mercato attuali non riflettono il loro valore a lungo termine. L'azienda prevede di continuare a raggiungere un effetto leva operativo e una riaccelerazione della crescita dei ricavi, enfatizzando il proprio impegno a creare valore sostenibile per azionisti, clienti e membri del team.
Health Catalyst (HCAT) ha anunciado una recompra de acciones por aproximadamente 5 millones de dólares, ejecutada entre el 3 y el 10 de marzo de 2025. La compañía retiró aproximadamente 1,1 millones de acciones ordinarias como parte de su programa de recompra de acciones existente, que fue autorizado en agosto de 2022 con una capacidad total de 40 millones de dólares.
El CEO Dan Burton afirmó que la recompra refleja la confianza de la empresa en su futuro, citando que los precios actuales del mercado no reflejan su valor a largo plazo. La compañía anticipa continuar logrando apalancamiento operativo y una re-aceleración del crecimiento de ingresos, enfatizando su compromiso de crear valor sostenible para accionistas, clientes y miembros del equipo.
Health Catalyst (HCAT)는 500만 달러 규모의 자사주 매입을 발표했으며, 이는 2025년 3월 3일부터 10일 사이에 실행되었습니다. 이 회사는 2022년 8월에 승인된 기존 자사주 매입 프로그램의 일환으로 약 110만 주의 보통주를 매입했습니다. 이 프로그램의 총 규모는 4000만 달러입니다.
CEO 댄 버튼은 이러한 매입이 회사의 미래에 대한 신뢰를 반영한다고 밝혔으며, 현재 시장 가격이 장기 가치를 반영하지 않는다고 언급했습니다. 이 회사는 운영 레버리지 달성과 수익 성장의 재가속화를 지속적으로 달성할 것으로 예상하며, 주주, 고객 및 팀원에게 지속 가능한 가치를 창출하기 위한 노력을 강조했습니다.
Health Catalyst (HCAT) a annoncé un rachat d'actions d'environ 5 millions de dollars, effectué entre le 3 et le 10 mars 2025. L'entreprise a retiré environ 1,1 million d'actions ordinaires dans le cadre de son programme de rachat d'actions existant, qui a été autorisé en août 2022 avec une capacité totale de 40 millions de dollars.
Le PDG Dan Burton a déclaré que ce rachat reflète la confiance de l'entreprise en son avenir, en précisant que les prix de marché actuels ne reflètent pas leur valeur à long terme. L'entreprise prévoit de continuer à réaliser un effet de levier opérationnel et une réaccélération de la croissance des revenus, en soulignant son engagement à créer une valeur durable pour les actionnaires, les clients et les membres de l'équipe.
Health Catalyst (HCAT) hat eine Aktienrückkäufe in Höhe von etwa 5 Millionen Dollar angekündigt, die zwischen dem 3. und 10. März 2025 durchgeführt werden. Das Unternehmen hat im Rahmen seines bestehenden Aktienrückkaufprogramms, das im August 2022 mit einem Gesamtvolumen von 40 Millionen Dollar genehmigt wurde, etwa 1,1 Millionen Aktien zurückgezogen.
CEO Dan Burton erklärte, dass der Rückkauf das Vertrauen des Unternehmens in seine Zukunft widerspiegelt und dass die aktuellen Marktpreise ihren langfristigen Wert nicht widerspiegeln. Das Unternehmen erwartet, weiterhin Betriebseffizienz und eine Beschleunigung des Umsatzwachstums zu erreichen und betont sein Engagement, nachhaltigen Wert für Aktionäre, Kunden und Teammitglieder zu schaffen.
- Repurchased and retired 1.1 million shares, reducing share count and potentially improving EPS
- Management confidence in company's future demonstrated through $5M buyback
- Anticipates continued operating leverage improvement
- Expects revenue growth reacceleration
- Only $5M of the $40M authorized buyback program utilized since August 2022
- Current market valuation deemed unfavorable by management
These repurchased shares were acquired between March 3, 2025, and March 10, 2025, as part of Health Catalyst's existing share repurchase program approved by its board of directors on August 2, 2022, which authorized repurchases of up to
"Our repurchase of shares underscores our confidence in the future of our business," said Dan Burton, CEO of Health Catalyst. "We believe the current market does not reflect the long-term value of our shares of common stock, including our anticipated continued achievement of operating leverage and our reacceleration of revenue growth. This repurchase demonstrates our continued commitment to creating long-term, sustainable value for our shareholders, our clients, and our team members."
About Health Catalyst
Health Catalyst (Nasdaq: HCAT) is a leading provider of data and analytics technology and services that ignite smarter healthcare, lighting the path to measurable clinical, financial, and operational improvement. More than 1,000 organizations worldwide rely on Health Catalyst's offerings, including our cloud-based technology ecosystem Health Catalyst Ignite™, AI-enabled data and analytics solutions, and expert services to drive meaningful outcomes across hundreds of millions of patient records. Powered by high-value data, standardized measures and registries, and deep healthcare domain expertise, Ignite helps organizations transform complex information into actionable insights. Backed by a multi-decade mission and a proven track record of delivering billions of dollars in measurable results, Health Catalyst continues to serve as the catalyst for massive, measurable, data-informed healthcare improvement and innovation.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to Health Catalyst's operating leverage, revenue growth and stock performance. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding Health Catalyst's future performance and opportunities. These forward-looking statements represent Health Catalyst's expectations as of the date of this press release, and involve risks, uncertainties and assumptions. The actual results may differ materially from those anticipated in the forward-looking statements as a result of numerous factors, many of which are beyond Health Catalyst's control. Important risks and uncertainties that could cause Health Catalyst's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to Health Catalyst's business model; (ii) changes in market or industry conditions, regulatory environment, and receptivity to Health Catalyst's technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key clients or partners; (v) macroeconomic challenges (including high inflationary and/or high interest rate environments, or market volatility caused by bank failures and measures taken in response thereto) and any new public health crisis; and (vi) changes to Health Catalyst's abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect Health Catalyst's actual results, please refer to the risk factors identified in Health Catalyst's SEC reports, including, but not limited to the Annual Report on Form 10-K for the year ended December 31, 2024 filed on February 26, 2025, available at www.sec.gov. While Health Catalyst may elect to update such forward-looking statements at some point in the future, Health Catalyst disclaims any obligation to do so, even if subsequent events cause Health Catalyst's views to change.
Investor Relations Contact:
Jack Knight
Vice President, Investor Relations
+1 (855)-309-6800
ir@healthcatalyst.com
Media Contact:
Kathryn Mykleseth
PR and Communications Director
media@healthcatalyst.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/health-catalyst-announces-5-million-stock-repurchase-302397725.html
SOURCE Health Catalyst
FAQ
How many shares did Health Catalyst (HCAT) repurchase in March 2025?
What is the total size of Health Catalyst's (HCAT) share repurchase program?
How much did Health Catalyst (HCAT) spend on its March 2025 stock buyback?
What is the strategic reason behind Health Catalyst's (HCAT) stock buyback?
